Samantha Fox
Nurse Practitioner · Gate City, VANPI 1023673407
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $142,875 of the $206,755 with a category attached, or 69.1%. Axsome Therapeutics, Inc. accounts for 66.9% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $143,905, more than ten times the $71 reported in 2022. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 648 payments — averaging $319.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$138K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$27K
- Supernus Pharmaceuticals, Inc.$24K
- AbbVie$16K
- Vanda Pharmaceuticals Inc.$505
- Alkermes, Inc.$390
- plus $1K from 10 others
What the payments were for
- Consulting fees$23,00011%
- Speaking & faculty fees$142,87569%
- Travel & lodging$29,90914%
- Food & beverage$10,9715%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 296 | $138,247 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 76 | $26,514 |
| Supernus Pharmaceuticals, Inc. | 69 | $24,177 |
| AbbVie | 135 | $15,780 |
| Vanda Pharmaceuticals Inc. | 14 | $505 |
| Alkermes, Inc. | 13 | $390 |
| Corium, LLC | 19 | $373 |
| E.r. Squibb & Sons, L.L.C. | 6 | $190 |
| Johnson & Johnson | 3 | $142 |
| Neuronetics, Inc. | 1 | $121 |
| Neurocrine Biosciences, Inc. | 5 | $116 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 2 | $20 |
| Boston Scientific | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$206,755 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 13 | $17,634 |
| Clonazepam | 95 | $843 |
| Quetiapine Fumarate | 24 | $308 |
| Diazepam | 30 | $173 |
| Divalproex Sodium | 12 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $15,780 | $17,63413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Gate City
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
- Kristin AustriaVirginia Beach$26K
- Racheal ValcourWinchester$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.